Characteristics of subjects with exercise-induced dyspnoea without EIB and EILO versus subjects with exercise-induced dyspnoea with EIB and/or EILO
| Exercise-induced dyspnoea without EIB or EILO | Exercise-induced dyspnoea with EIB and/or EILO | p Value | |
|---|---|---|---|
| Subjects, n (%) | 41 (49.4) | 42 (50.6) | |
| Age (years), mean (min, max) | 14.29 (13, 15) | 14.24 (13, 15) | 0.67 |
| Girls, n (%) | 19 (46.3) | 30 (71.4) | 0.026 |
| BMI, mean (SD) | 20.8 (3.1) | 21.1 (2.2) | 0.53 |
| FEV1% predicted*, mean (SD) | 91.9 (12.0) | 91.1 (9.5) | 0.94 |
| Ever asthma†, n (%) | 16 (39.0) | 19 (45.2) | 0.66 |
| Inhaled corticosteroids‡, n (%) | 7 (17.1) | 12 (28.6) | 0.30 |
| SABA‡, n (%) | 19 (46.3) | 19 (45.2) | >0.99 |
| LABA‡, n (%) | 2 (4.9) | 0 | 0.24 |
| LTRA‡, n (%) | 2 (4.9) | 3 (7.1) | >0.99 |
*Recorded before exercise-induced bronchoconstriction test.
†Self-reported, physician diagnosed.
‡Self-reported, any use in last 3 months.
Regarding self-reported exercise-induced symptoms, there were no differences between participants with exercise-induced dyspnoea who did or did not have EIB or EILO regarding exercise wheeze, chest tightness, cough, throat tightness, choking sensation, hoarse voice or inspiratory stridor.
BMI, body mass index (kg/m2); EIB, exercise-induced bronchoconstriction; EILO, exercise-induced laryngeal obstruction; LABA, long-acting bronchodilator agent; LTRA, leukotriene receptor antagonist; SABA, short acting bronchodilator agent.